Table 2.

Treatment regimen composition and characteristics

Treatment Regimen Intensive phase/Continuation phase	Total patients (n = 165)a
6 to <9 Months (n, %)
(H)RZE/(H)RE	8 (4.8)
(H)RZE/(H)RZE	6 (3.6)
(H) RZEQ/REQ	6 (3.6)
Other	1 (0.2)
≥ 9 to ≤12 Months (n, %)
(H)RZE/(H)RE	32 (19.4)
(H)RZE/(H)RZE	35 (21.2)
(H)RZE(Q)/(H)REQ	14 (8.5)
(H)RZE(Q)/(H)RZEQ	10 (6.1)
(H)RE/(H)RE	4 (2.4)
Other	17 (10.3)
> 12 Months (n, %)
(H)RZE/(H)RE	1 (0.2)
(H)RZE/(H)RZE	6 (3.6)
(H)RZE(Q)/(H)REQ	4 (2.4)
Other	15 (9.1)

I isoniazid, P pyrazinimide, R rifampin, E ethambutol, Q fluoroquinolone, S streptomycin

^a6 (3.6%) patients were on treatment for <6 months due to treatment non-completion or death